Dataset opportunity
Ceryxmedical — 医疗影像数据集机会
Ceryxmedical 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
69.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球诊断人工智能市场规模在 2025 年估值为 20 亿美元，预计到 2033 年将达到 97 亿美元，复合年增长率为 21.7%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 🤝Data partnership
与奥克兰大学合作进行生理学研究
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Ceryxmedical 持有一个独特的医疗影像数据集，该数据集源自敏感的生理信号，包括其临床前和临床试验的 `iot_data` 和 `medical_records`。这些高价值数据专注于用于心脏节律控制的生物电子信号，其结构旨在开发和验证诊断人工智能模型，并且相关的监管文件进一步增强了其可用性。
全球诊断人工智能市场在 2025 年的估值为20 亿美元，预计到 2033 年将以21.7% 的复合年增长率增长。[1] 尽管由于 GDPR、临床试验数据的道德合规性以及专有算法的相互关联，存在严格的访问条件，但该数据集的稀有性和特异性使其成为旨在进入如此显著增长的市场进行创新的买家的关键资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据涉及来自临床前和临床试验的敏感生理信号；高度监管的医疗器械行业需要严格遵守 GDPR 和道德规范进行数据传输；专有生物电子信号处理算法可能与原始数据相互关联。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Ceryxmedical 拥有一个以心力衰竭为中心、多模态的专有数据集。它独特地结合了高分辨率的心脏记录、专利的生物电子时间序列数据以及来自临床试验的信息。对于旨在开发和验证针对心脏领域的复杂预测模型的诊断人工智能公司来说，这是一个稀有且强大的资产，而心脏领域是人工智能诊断市场的主要驱动力，预计到 2033 年将达到97 亿美元。
See dimension details ↓- Dataset Specificity90
主导的“medical_records”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求异常高，这得益于诊断人工智能市场的快速扩张，该市场正以 21.7% 的复合年增长率增长。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Ceryx Medical 是一个不错的目标，因为它是一家开发实体医疗设备（起搏器）的中小企业，所产生的有价值的临床试验数据是其核心运营业务的副产品，而不是其主要销售产品。
- Deep Qualification70
⚠ 需要审查 — Ceryx Medical 是一家医疗设备开发商，其核心业务是销售生物电子起搏器，而不是数据。它拥有来自其临床前和人体试验的生理信号的有价值的副产品数据集，但“医疗影像”标签不正确。由于临床试验协议和患者同意的复杂性，数据所有权可能混合且许可权不明确。[数据集类型与实际活动不符：该公司的产品 Cysoni 监测和处理来自心肺系统的生理信号，这是时间序列数据，而不是“医疗影像数据集”。[7, 8]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该数据集包含高分辨率的心脏功能记录，包括来自临床心力衰竭模型的房颤变异性，提供了训练人工智能进行早期准确疾病检测所需的详细信息。
IoT / sensor data
这些证据指向来自专利生物电子设备的独家时间序列数据，这些设备监测稳态系统相互作用，为开发预测性和个性化诊断算法提供了独特的实时生理信号。
Regulatory records
该数据集丰富了来自临床试验的数据，这些试验侧重于改善心力衰竭患者的治疗效果，对于任何需要根据真实世界治疗干预措施验证模型性能和有效性的人工智能开发者来说，这是一个关键资产。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Ceryxmedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global artificial intelligence in diagnostics market size was valued at USD 2.0 billion in 2025, projected to reach USD 9.7 billion by 2033, at a CAGR of 21.7% (source: Grand View Research). [1]. Investment score 69.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Broekmanlogistics — 工业运营数据集机会
View opportunity →工业Rocklink — 工业运营数据集机会
View opportunity →工业Anumar — 工业传感器数据集机会
View opportunity →